OS Therapies Incorporated, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jason McCarthy has given his Buy rating due to a combination of factors surrounding OS Therapies Incorporated’s recent developments. The company has announced promising interim results from its Phase 2b trial of OST-HER2, a novel cancer immunotherapy targeting HER2-expressing cancer cells in recurrent osteosarcoma. The data revealed that 66.6% of patients treated with OST-HER2 achieved a 2-year overall survival rate, significantly higher than the 40% observed in historical controls, indicating a strong therapeutic potential.
Additionally, OS Therapies is making strides towards regulatory approval, with an End-of-Phase 2 meeting with the FDA scheduled and a BLA number already assigned, suggesting a favorable pathway for accelerated approval. The OST-HER2 therapy holds several FDA designations, including Orphan, Fast Track, and Rare Pediatric Disease, which could lead to a priority review voucher, offering a substantial non-dilutive capital opportunity. These factors, combined with the significant unmet medical need in osteosarcoma treatment, underpin McCarthy’s optimistic outlook and Buy rating for the stock.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OSTX in relation to earlier this year.